Bicara Therapeutics

BCAX · NASDAQ

$18.35+$0.88 (+5.04%)TodayMarket closed ·
Prev close $17.47

Latest news

  • NewsAvi Kapoor

    Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

  • Press releaseGlobe Newswire

    Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

  • Press releaseGlobe Newswire

    Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

  • Press releaseGlobe Newswire

    Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

  • Press releaseGlobe Newswire

    Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

  • News

    Earnings Scheduled For May 11, 2026

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

  • News

    Earnings Scheduled For March 30, 2026

  • Press releaseGlobe Newswire

    Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

  • Press releaseGlobe Newswire

    Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

  • Press releaseGlobe Newswire

    Bicara Therapeutics Announces Proposed Public Offering of Common Stock

  • Press releaseGlobe Newswire

    Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

  • Press releaseGlobe Newswire

    Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

  • Press releaseGlobe Newswire

    Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

  • Press releasePRNewswire

    Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

  • Press releasePRNewswire

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

  • Press releaseBusiness Wire

    Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

  • NewsAvi Kapoor

    Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook

  • NewsAvi Kapoor

    Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results

  • NewsAvi Kapoor

    Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • News

    Market-Moving News for May 23rd

  • NewsAvi Kapoor

    This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

  • Press releaseGlobe Newswire

    Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • NewsAvi Kapoor

    Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • NewsAvi Kapoor

    This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

  • NewsAvi Kapoor

    This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.